Pipeline
A pipeline of powerful possibilities.
Our dynamic portfolio of virology assets includes a pipeline focused on curing HBV. Today, we have several active clinical studies, including approaches combining different mechanisms of action to achieve our therapeutic goals.

Lead Optimization
IND Enabling
Phase 1
Phase 2
Phase 3
Marketed
RNAi Therapeutic
Imdusiran (AB-729) cHBV
Imdusiran (AB-729) cHBV
Imdusiran (AB-729) cHBV
PD-L1 Inhibitor
AB-101
All Arbutus clinical trials are conducted in compliance with the Declaration of Helsinki and the ICH Guideline for Good Clinical Practice